III期CheckMate 649试验的12.1个月的随访结果提示,在PD-L1联合阳性评分(CPS)≥5的患者中,纳武利尤单抗联合化疗就已在总生存期(OS)、无进展生存期(PFS)等疗效指标上有所改善;CheckMate 649试验的患者报告的结局(PRO)中也提示接受纳武利尤...
2. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, ...
2. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, ...
2024年2月,《Journal of Clinical Oncology》杂志发表了题为《First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial...
2. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, ...
[2]. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised...
近期,国际知名期刊Natrue报道了CheckMate-649研究[3]的长期随访数据,主要报告了纳武利尤单抗联合化疗与单独化疗的长期随访结果。医学界肿瘤频道特邀北京大学肿瘤医院张小田教授就CheckMate-649研究此次公布的最新研究数据进行解读分析。 中西方胃癌患...
推荐原因:目前CheckMate 649试验的主要结果、亚组分析和患者报告结局等结果均已公布,本次3年随访结果的更新评估了纳武利尤单抗联合化疗方案作为晚期或转移性胃/胃食管交界处腺癌/食管腺癌患者的一线治疗的长期疗效,不断刷新晚期胃癌一线免疫治疗最长随访纪录。另外,该试验的4年随访数据和中国亚组分析也在2024年ASCO GI大...
2024年ASCO GI大会上,CheckMate-649研究公布了胃癌免疫治疗领域首个4年长期随访数据;我们特邀CheckMate-649中国主要研究者——北京大学肿瘤医院消化肿瘤内科主任沈琳教授就该结果分享感受与见解。 专家简介 我国是胃癌高发国家,大量患者确诊...
1. Yelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate ...